ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0053

Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis

RA – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 0242

Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0023

New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0182

Newly Diagnosed with Inflammatory Arthritis. Development of a Complex Self-management Intervention

Patient Education/Community Programs Poster

1:00PM-3:00PM: Abstract Number: 0429

No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis

Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

1:00PM-3:00PM: Abstract Number: 0043

Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0207

Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0151

Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0251

Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0153

Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0314

Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0313

Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0230

Online Educational Module on Axial Spondyloarthritis Improves the Knowledge and Confidence of Non-rheumatology Providers

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0215

Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0435

Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].